Scientific Publication

First-in-Human Clinical Results Published in The Journal of Clinical Pharmacology and Presented at WCP2026 T-E Pharma’s subsidiary, Immunwork, Inc., announced that the First-in-Human (FIH) Phase 1/2a clinical study results of TE-8105, a long-acting GLP-1 receptor agonist developed using Immunwork’s proprietary technology platform, have been published in the internationally recognized journal The Journal of Clinical Pharmacology. The publication, entitled […]

T-E Pharma is honored to be invited by the Journal of the Chinese Chemical Society (JCCS) to publish a review article introducing our core technology platform “Multi-Arm Linkers”, highlighting its innovative design and broad applications in novel drug development. JCCS is one of Taiwan’s longest-established SCI-indexed chemistry journals. It is published by the Chemical Society

Great news! The long-acting GLP-1 receptor agonist TE-8105 has achieved an innovative breakthrough in formulation development, successfully creating a more convenient sublingual delivery form! We are thrilled to announce the publication of our paper, entitled “Optimized sublingual delivery of dual fatty acid-conjugated GLP-1 receptor agonist TE-8105 produces durable efficacy in diabetic mice”, has been published

Great News! Immunwork’s Latest Publication Offers a Promising Clinical Solution for Diabetes, Obesity, and NASH Disease! The study, titled “2FA-Platform Generates Dual Fatty Acid-Conjugated GLP-1 Receptor Agonist TE-8105 with Enhanced Diabetes, Obesity, and NASH Efficacy Compared to Semaglutide,” has been published in the prestigious Journal of Medicinal Chemistry. Led by Dr. Wun-Teng Wong, Manager of

Exciting news! Our latest published paper offers promising solutions for multiple myeloma treatment through ADC technology platform! We are thrilled to announce the publication of our paper “An Antibody-Drug Conjugate for Multiple Myeloma Prepared by Multi-Arm Linkers” in the prestigious Advanced Science journal. Led by Dr. Allen Yueh-Hsiang Yu, our Senior Manager of Preclinical Development

Exciting News! Immunwork’s Latest Published Paper Offers Promising Solutions for Pancreatic Cancer Treatment, Diagnostics, and Applications in ADC and ARC! We are thrilled to announce the publication of our paper, “Site-specific Conjugation of 6 DOTA Chelators to a CA19-9-targeting scFv-Fc Antibody for Imaging and Therapy,” in the prestigious Journal of Medicinal Chemistry. Led by Dr.